News Health/Medical Can a Vaccine Protect Against Dementia? Insights from GSK's Shingrix
0
Dementia

Published :

Can a Vaccine Protect Against Dementia? Insights from GSK's Shingrix

By Brett Arends

Data show a correlation between use of a common vaccine and lower risk of getting dementia, according to company chief commercial officer Luke Miels from GlaxoSmithKline (GSK).

The Dementia Challenge

Dementia affects millions worldwide, causing immense suffering. Despite extensive research, its exact cause remains elusive.

Shingrix: A Surprising Connection

GSK's shingles vaccine, Shingrix, has been in the spotlight. Internal data suggests a correlation between Shingrix usage and reduced dementia risk. Miels emphasizes that this finding is not isolated; previous population-based studies have hinted at a similar link.

Real-World Experiment

A groundbreaking study involving over five million seniors in Great Britain revealed that those vaccinated against shingles were 20% less likely to develop dementia over seven years. The study capitalized on a natural experiment: the 2013 rollout of shingles vaccines for specific birth cohorts.

Hope on the Horizon

GSK is actively investigating whether Shingrix could be a transformational treatment for dementia prevention. While more research is needed, the possibility of leveraging an existing vaccine offers hope in the fight against this devastating condition.

  • Reactions

    0
    0
    0
    0
    0
    0

    Your email address will not be published. Required fields are marked *